Literature DB >> 6184562

Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.

G Muiesan, E Agabiti-Rosei, M Castellano, C L Alicandri, L Corea, R Fariello, M Beschi, G Romanelli.   

Abstract

The aim of this study was to investigate and compare the effects of two calcium antagonist drugs, verapamil (VER) and nifedipine (NIF), on blood pressure (BP), heart rate (HR), plasma catecholamines (pCA), renin (PRA), plasma aldosterone (pALD), and plasma volume (PV) in a group of patients with mild to moderate essential hypertension. In 12 hypertensive patients on a fixed normal sodium and potassium intake, VER (80 mg t.i.d., per os) first and then NIF (10 mg, t.i.d. per os), or vice versa according to a random sequence, were each given for 8 days, with an interval of 5 days between the two treatments. Both NIF and VER significantly reduced BP (p less than 0.001); this reduction was quantitatively similar in both treatment schedules. Supine and standing PRA, pALD, and PV were not significantly affected by VER or NIF. HR and pCA were unchanged after VER, whereas they were significantly increased (p less than 0.05, at least) mainly in standing position after NIF treatment. The antihypertensive and metabolic effects of VER (80 mg t.i.d.) and NIF (10 mg t.i.d.) were maintained after chronic treatment (4 months with VER in 10 patients and 2 months with NIF in 12 patients). After 2 months of treatment with VER (160 mg t.i.d.) in 18 patients, BP was further reduced, while pCA were slightly increased. In conclusion, VER and NIF are effective and equipotent antihypertensive agents that do not induce significant renin stimulation or fluid retention; adrenergic stimulation seems to be greater with NIF, which should be taken into account in the clinical use of these drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184562

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  17 in total

1.  Long-term therapy with slow-release nifedipine in essential hypertension.

Authors:  F Arrigo; F Consolo
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Co-dergocrine mesylate inhibits the increase in plasma catecholamines caused by nifedipine in essential hypertension.

Authors:  R Kirsten; K Nelson; G Weidinger; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

4.  The effect of 8 weeks treatment with the calcium antagonist felodipine on blood pressure, heart rate, working capacity, plasma renin activity, plasma angiotensin II, urinary catecholamines and aldosterone in patients with essential hypertension.

Authors:  P L Katzman; U L Hulthén; B Hökfelt
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

Review 5.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 6.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 7.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

8.  Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.

Authors:  G Muiesan; R Fariello; M L Muiesan; O E Christensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Nitrendipine and the humoral control of sodium homeostasis.

Authors:  D R Forsyth; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.